Neurologic clinical trials - UCB MG0003 Rozanolixizumab

Status:

Open (Study open and enrolling)

ClinicalTrials.gov:

NCT03971422

CONDITION(S): Myasthenia Gravis, Generalized Myasthenia Gravis - TRIAL: UCB MG0003 Rozanolixizumab - A Randomized, double-blind, placebo-controlled, dose-ranging (adaptive design) study evaluating efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravis

Drug

Drug: Arimoclomol, Placebo oral capsule

Trial Type

Interventional

Condition

Generalized Myasthenia Gravis (gMG) Myasthenia Gravis

Keywords

Generalized Myasthenia Gravis (gMG) | UCB | Myasthenia Gravis | Rozanolixizumab